<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Asymptomatic left ventricular diastolic dysfunction
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Asymptomatic left ventricular diastolic dysfunction
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Asymptomatic left ventricular diastolic dysfunction
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barry A Borlaug, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Frederick Masoudi, MD, MSPH, FACC, FAHA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H295420249">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heart failure (HF) afflicts six million Americans and represents one of the leading causes of hospitalization among older adults [
         <a href="#rid1">
          1
         </a>
         ]. Symptomatic HF (stage C and stage D) is commonly preceded by a stage in which cardiac dysfunction is present, but symptoms are absent (stage B) [
         <a href="#rid2">
          2,3
         </a>
         ]. With the widespread utilization of echocardiography, asymptomatic cardiac dysfunction is commonly identified. This topic discusses identification, prognosis, and management of asymptomatic left ventricular (LV) diastolic dysfunction (ALVDD). (See
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy", section on 'Stages in the development of HF'
         </a>
         .)
        </p>
        <p>
         Other syndromes of LV dysfunction are discussed separately, including (see
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HF with preserved ejection fraction and other causes of HF with normal or near normal ejection fraction. (See
         <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">
          "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3457.html" rel="external">
          "Pathophysiology of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HF with reduced ejection fraction. (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HF with mid-range ejection fraction. (See
         <a class="medical medical_review" href="/z/d/html/117708.html" rel="external">
          "Treatment and prognosis of heart failure with mildly reduced ejection fraction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic LV systolic dysfunction and asymptomatic valvular heart disease are discussed in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/3490.html" rel="external">
          "Approach to diagnosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">
          "Management and prognosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1168600480">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         LV diastolic dysfunction (LVDD) refers broadly to abnormalities in myocardial relaxation, compliance, and filling [
         <a href="#rid4">
          4
         </a>
         ]. LVDD is most commonly identified by echocardiography  (
         <a class="graphic graphic_figure graphicRef72146" href="/z/d/graphic/72146.html" rel="external">
          figure 1
         </a>
         ). LVDD can cause increased LV diastolic filling pressure, which in turn can increase pulmonary capillary pressure, resulting in lung congestion and dyspnea [
         <a href="#rid5">
          5-7
         </a>
         ]. (See
         <a class="local">
          'Echocardiographic criteria for LVDD'
         </a>
         below.)
        </p>
        <p>
         The American College of Cardiology/American Heart Association guidelines endorse a staging system for HF based upon the progressive nature of this syndrome [
         <a href="#rid2">
          2
         </a>
         ]. Stage A refers to asymptomatic patients with HF risk factors but normal cardiac structure and function. Stage B includes asymptomatic patients with cardiac structural or functional abnormalities. Asymptomatic LVDD (ALVDD) is one of the clinical presentations for stage B HF [
         <a href="#rid8">
          8-10
         </a>
         ]. Stage C refers to symptomatic HF, and stage D refers to refractory HF requiring specialized interventions. A later consensus document from the Heart Failure Society of America, the Heart Failure Association of the European Society of Cardiology, and the Japanese Heart Failure Society refers to stage A as "at risk" for HF and stage B as "pre-HF" [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">
          "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1029458597">
         <span class="h1">
          PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of ALVDD varies depending upon the criteria used to identify ALVDD (see
         <a class="local">
          'Echocardiographic criteria for LVDD'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of stringency of criteria
         </strong>
         – The prevalence of ALVDD is lower when more stringent (more specific and less sensitive) criteria are applied to identify LVDD. The prevalence of ALVDD in adult populations (with mean ages 53 to 73) ranged from 25 to 35 percent using echocardiographic criteria included in the 2009 American Society of Echocardiography (ASE)/European Association of Echocardiography guidelines [
         <a href="#rid12">
          12-16
         </a>
         ]. Application of the more stringent 2016 ASE/European Association of Cardiovascular Imaging guideline criteria for LVDD [
         <a href="#rid17">
          17
         </a>
         ] resulted in a dramatic reduction in the prevalence of ALVDD, decreasing from 38.1 percent with the 2009 criteria to 1.4 percent with the 2016 criteria [
         <a href="#rid18">
          18,19
         </a>
         ]. However, the greater specificity of the 2016 criteria may have compromised sensitivity, as the prevalence of ALVDD according to this definition is lower than the general population prevalence of symptomatic (ie, stage C) HF, estimated at 2.4 to 3.0 percent [
         <a href="#rid1">
          1
         </a>
         ]. As such, many echocardiography laboratories continue to use the earlier, broader criteria for LVDD, as discussed below. (See
         <a class="local">
          'Detection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of adjustment for age
         </strong>
         – The frequency of ALVDD increases strikingly with age and with comorbidities such as obesity, coronary heart disease, atrial fibrillation, hypertension, and chronic kidney disease. Some clinical investigators have proposed age-specific cut-points for LVDD, resulting in a much less striking increase in the prevalence of LVDD with aging [
         <a href="#rid20">
          20,21
         </a>
         ]. However, conditions associated with LVDD, particularly HF with preserved ejection fraction (HFpEF), also increase with age [
         <a href="#rid1">
          1
         </a>
         ], and classification of age-related LVDD as "normal" could have the unintended consequence of undermining clinical detection of LVDD and HFpEF [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">
          "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2300338408">
         <span class="h1">
          DETECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALVDD is identified in individuals who have LVDD and lack symptoms of HF.
        </p>
        <p class="headingAnchor" id="H515425763">
         <span class="h2">
          Identification of LVDD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echocardiography is the key test for identification of LVDD, assessment of LV ejection fraction, and identification or exclusion of other cardiac abnormalities. LVDD is commonly detected as an incidental finding in patients undergoing transthoracic echocardiography for other indications. An evaluation of diastolic function is a standard component of a complete echocardiographic examination [
         <a href="#rid3">
          3,4,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5304.html" rel="external">
          "Echocardiographic evaluation of left ventricular diastolic function in adults", section on 'When to evaluate diastolic function'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3993030833">
         <span class="h3">
          Echocardiographic criteria for LVDD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echocardiographic findings associated with LVDD include alterations in the pattern of diastolic blood inflow across the mitral valve into the LV, abnormalities in the pulmonary venous inflow pattern, and reductions in diastolic tissue velocities. When sustained over time, worsening LVDD causes left atrial enlargement and increases in pulmonary artery pressure, which can also be detected using echocardiography. Details on the detection of LVDD by echocardiography are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5304.html" rel="external">
          "Echocardiographic evaluation of left ventricular diastolic function in adults"
         </a>
         .)
        </p>
        <p>
         The definition of LVDD has evolved over the past two decades. LVDD was initially defined by abnormalities in the transmitral and pulmonary venous inflow patterns along with tissue Doppler velocities, as described in the 2009 American Society of Echocardiography (ASE) recommendations for evaluation of diastolic function [
         <a href="#rid12">
          12,13
         </a>
         ]. The 2018 updated ASE guidelines established a more stringent definition for diastolic dysfunction [
         <a href="#rid17">
          17
         </a>
         ], which has affected the apparent prevalence of LVDD, as discussed above [
         <a href="#rid18">
          18,19
         </a>
         ]. (See
         <a class="local">
          'Prevalence'
         </a>
         above and
         <a class="local">
          'Detection'
         </a>
         above.)
        </p>
        <p>
         As noted above, echocardiographic criteria for LVDD included in the 2009 ASE guidelines [
         <a href="#rid13">
          13
         </a>
         ] are more sensitive and less specific than the criteria for LVDD in the 2016 ASE guidelines [
         <a href="#rid17">
          17
         </a>
         ]. Indeed, even among patients with symptomatic (stage C) HF with preserved ejection fraction (HFpEF), the 2016 ASE criteria are insufficiently sensitive to identify patients with abnormal hemodynamics. A study found that the 2016 criteria for LVDD had a sensitivity of 34 percent and specificity of 83 percent in 50 patients with invasively proven HFpEF and 24 patients with dyspnea but no cardiac abnormality [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Given the limited sensitivity of the 2016 criteria for LVDD and use of earlier broader criteria (included in the 2009 ASE guidelines) in most prior studies, our echocardiography laboratory and many others continue to utilize the earlier, broader criteria for LVDD based primarily on Doppler interrogation of the mitral inflow pattern  (
         <a class="graphic graphic_figure graphicRef72146" href="/z/d/graphic/72146.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5304.html" rel="external">
          "Echocardiographic evaluation of left ventricular diastolic function in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1909648139">
         <span class="h3">
          Concurrent findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echocardiography also enables identification of cardiac findings commonly associated with LVDD, including LV hypertrophy (common in patients with hypertension) and systolic dysfunction (including regional abnormalities caused by coronary heart disease). (See
         <a class="medical medical_review" href="/z/d/html/5304.html" rel="external">
          "Echocardiographic evaluation of left ventricular diastolic function in adults", section on 'Detection and evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2112.html" rel="external">
          "Left ventricular hypertrophy: Clinical findings and ECG diagnosis"
         </a>
         .)
        </p>
        <p>
         Some patients with LVDD have regional or global systolic dysfunction. The evaluation and management of the asymptomatic and symptomatic patients with systolic dysfunction are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3490.html" rel="external">
          "Approach to diagnosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">
          "Management and prognosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3613063529">
         <span class="h3">
          Other cardiac tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other cardiac tests can detect diastolic dysfunction but are not routinely used to detect ALVDD.
        </p>
        <p>
         The gold standard method for assessment of diastolic function is cardiac catheterization, which enables simultaneous assessment of LV pressure and volume [
         <a href="#rid24">
          24
         </a>
         ]. However, this procedure is generally not performed to screen asymptomatic individuals. Elevations in LV diastolic filling pressure are occasionally noted during cardiac catheterization performed for other reasons (eg, coronary angiography to assess for coronary artery disease). (See
         <a class="medical medical_review" href="/z/d/html/1515.html" rel="external">
          "Cardiac catheterization techniques: Normal hemodynamics"
         </a>
         .)
        </p>
        <p>
         Cardiovascular magnetic resonance imaging (CMR) offers a variety of methods to detect abnormalities in LV structure and function, as well as myocardial fibrosis (via extracellular volume computation) associated with diastolic dysfunction, but these methods are not generally used to evaluate asymptomatic individuals [
         <a href="#rid25">
          25,26
         </a>
         ]. Nuclear scintigraphic methods for assessment of diastolic function have been proposed but are not established [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H795033509">
         <span class="h2">
          Exclusion of symptoms of HF
         </span>
         <span class="headingEndMark">
          —
         </span>
         A careful clinical evaluation is required to determine whether a patient has symptoms of HF; this includes taking a history to elicit symptoms and, for patients with uncertain activity tolerance, an exercise evaluation to delineate any functional limitations [
         <a href="#rid29">
          29
         </a>
         ]. Many patients deny symptoms of dyspnea but may be highly sedentary, potentially obscuring activity intolerance. Evaluation with exercise testing or even a simple hall walk may reveal significant limitations in activity tolerance, thus revealing that the patient has occult HF with symptoms that may have been minimized or ignored [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Patients with activity intolerance and dyspnea merit further evaluation for HF and other causes, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">
          "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2188091326">
         <span class="h1">
          MANAGEMENT PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of patients with ALVDD includes therapeutic lifestyle changes, treatment of comorbid conditions, monitoring for symptoms and signs of progression to HF, and prompt evaluation and treatment of incident HF.
        </p>
        <p class="headingAnchor" id="H2950965259">
         <span class="h2">
          Therapeutic lifestyle changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic life-style changes may reduce the risk of progression to HF. An analysis from the ARIC cohort including 13,462 adults found that greater adherence to the American Heart Association's Life's Simple 7 guidelines on smoking, body mass, physical activity, diet, cholesterol, blood pressure, and glucose in middle age was associated with lower lifetime occurrence of HF and preservation of cardiac function [
         <a href="#rid30">
          30
         </a>
         ]. The lifetime heart failure risk was 14.4 percent for those with an optimal middle-age Life's Simple 7 score, 26.8 percent for an intermediate score, and 48.6 percent for an inadequate score. This finding was confirmed in a prospective cohort study from Europe, in which optimal and intermediate Life’s Simple 7 scores were associated with reduced risk for HF compared with an inadequate score (hazard ratio [HR] 0.45, 95% CI 0.34-0.60 and HR 0.53, 95% CI 0.44-0.64, respectively) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Greater physical activity may reduce the risk of HF. A randomized trial in 61 healthy, sedentary, middle-aged participants found that two years of exercise training improved maximal oxygen uptake and decreased cardiac stiffness [
         <a href="#rid32">
          32
         </a>
         ]. An observational study following 13,810 participants for a median of 26 years found that recommended levels of physical activity were associated with lower HF risk among individuals with hypertension, obesity, diabetes, or metabolic syndrome, but not among those with prevalent atherosclerotic cardiovascular disease (coronary heart disease, stroke, or peripheral arterial disease) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2086714167">
         <span class="h2">
          Management of comorbidities
         </span>
         <span class="headingEndMark">
          —
         </span>
         As ALVDD is strongly associated with comorbid conditions such as hypertension, diabetes mellitus, coronary heart disease, and obesity, care of individuals with ALVDD involves management of these comorbidities [
         <a href="#rid2">
          2
         </a>
         ]. Treatment of these conditions improves cardiovascular outcomes, and some of these measures reduce the risk of developing HF:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of hypertension. (See
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">
          "Goal blood pressure in adults with hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Standard recommendations for management of hypertension apply to patients with ALVDD. Antihypertensive therapy is central to reducing the risk of developing heart failure [
         <a href="#rid34">
          34,35
         </a>
         ], as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">
          "Goal blood pressure in adults with hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3838.html" rel="external">
          "Treatment of hypertension in patients with heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of diabetes mellitus and treatment of diabetic kidney disease. (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">
          "Treatment of diabetic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As noted below, patients with diabetes are at high risk for development HF in the setting of ALVDD [
         <a href="#rid36">
          36
         </a>
         ] (see
         <a class="local">
          'Prognosis'
         </a>
         below). Management of hyperglycemia in patients with type 2 diabetes and ALVDD is generally the same as for other patients at risk for developing HF, including use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         (the initial agent for most patients; use associated with lower cardiovascular risk compared with other initial agents) and sodium-glucose cotransporter 2 [SGLT2] inhibitors (which reduce the risk of HF and the risk of kidney failure). The use and effects of metformin and SGLT2 inhibitors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Initial pharmacologic therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Established cardiovascular or kidney disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">
          "Metformin in the treatment of adults with type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">
          "Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">
          "Treatment of diabetic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of atherosclerotic cardiovascular risk to guide primary (or secondary) prevention including lipid therapy and use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1468.html" rel="external">
          "Overview of atherosclerotic cardiovascular risk factors in females"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The presence of ALVDD does not modify the approach to statin therapy. While there are theoretical mechanisms whereby statins may exert benefits, their role in reducing the risk of HF has not been established. Studies evaluating the effects of statin therapy on the risk of HF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1493.html" rel="external">
          "Statin therapy in patients with heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The presence of ALVDD does not modify the approach to antiplatelet therapy. The effects of antithrombotic therapy in patients with HF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">
          "Aspirin in the primary prevention of cardiovascular disease and cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">
          "Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3502.html" rel="external">
          "Antithrombotic therapy in patients with heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of coronary heart disease. (See
         <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">
          "Chronic coronary syndrome: Overview of care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1520.html" rel="external">
          "Management of coronary heart disease in women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of obesity. Studies in people with obesity suggest that weight loss has beneficial hemodynamic effects and may reduce the risk of HF [
         <a href="#rid37">
          37-40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of LV systolic dysfunction. Some patients with ALVDD have regional or global systolic dysfunction. The evaluation and management of asymptomatic LV systolic dysfunction are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3490.html" rel="external">
          "Approach to diagnosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">
          "Management and prognosis of asymptomatic left ventricular systolic dysfunction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1894617751">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with ALVDD should be monitored clinically for symptoms and signs of progression to symptomatic HF in concert with follow-up and management of any associated comorbidities. Patients should receive counseling on the risk of HF and the importance of seeking medical care for HF symptoms. As noted above, careful evaluation of symptoms is required to identify patients with occult HF. (See
         <a class="local">
          'Exclusion of symptoms of HF'
         </a>
         above.)
        </p>
        <p>
         The recommended frequency of monitoring varies depending upon the presence and severity of concurrent conditions, ranging from annual visits (eg, for adults ≥50 years old with no chronic conditions), to two or more times per year (eg, for those on a stable antihypertensive regimen), to at least monthly (eg, for titration of antihypertensive therapy to reach goal blood pressure). (See
         <a class="medical medical_review" href="/z/d/html/97819.html" rel="external">
          "Overview of preventive care in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Blood pressure goals (targets)'
         </a>
         .)
        </p>
        <p>
         Follow-up echocardiography is performed only as clinically indicated to evaluate changes in clinical status (eg, new symptoms of HF). (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults", section on 'Diagnosis'
         </a>
         and
         <a class="local">
          'Progression to HF'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2054345662">
         <span class="h2">
          Progression to HF
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who develop symptoms and/or signs of HF require evaluation to determine whether HF is present, the cause of HF, and the appropriate treatment, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">
          "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">
          "Approach to diagnosis and evaluation of acute decompensated heart failure in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         .)
        </p>
        <p>
         Management of HF is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117708.html" rel="external">
          "Treatment and prognosis of heart failure with mildly reduced ejection fraction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3454.html" rel="external">
          "Treatment of acute decompensated heart failure: General considerations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3748199842">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with ALVDD have poorer exercise capacity compared with those with normal diastolic function indices [
         <a href="#rid8">
          8,26
         </a>
         ] and are at increased risk for progression to symptomatic HF [
         <a href="#rid36">
          36,41-44
         </a>
         ] and for death [
         <a href="#rid12">
          12,45
         </a>
         ]. In a community-based sample, the presence of mild LVDD was associated with an 8.3-fold increased risk for death (hazard ratio [HR] 8.31, 95% CI 3.00-23.1), while moderate to severe LVDD was associated with a 10.2-fold greater risk of death (HR 10.17, 95% CI 3.28-31.0) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         LVDD typically worsens with age, particularly among patients with obesity and weight gain [
         <a href="#rid46">
          46,47
         </a>
         ], and progression in LVDD over time is associated with substantially increased risk of death [
         <a href="#rid45">
          45
         </a>
         ]. In the community-based sample described above [
         <a href="#rid12">
          12
         </a>
         ], worsening LVDD was associated with age ≥65 years (odds ratio 2.85, 95% CI 1.77-4.72) as well as the presence of hypertension, diabetes, and coronary heart disease [
         <a href="#rid41">
          41
         </a>
         ]. ALVDD was independently associated with an 81 percent greater risk for developing incident HF (HR 1.81, 95% CI 1.01-3.48) after adjustment for other factors. Other studies have confirmed these findings, showing high risk for progression to HF among patients with ALVDD, particularly when associated with kidney disease, higher pulmonary artery pressures, respiratory limitations, and anemia [
         <a href="#rid42">
          42-44
         </a>
         ].
        </p>
        <p>
         Risk of progression to HF from ALVDD is particularly high among individuals with diabetes mellitus. A study of 1760 individuals with diabetes without HF found that 36.9 percent of those with ALVDD developed symptomatic HF within five years, compared with 16.8 percent for patients without LVDD [
         <a href="#rid36">
          36
         </a>
         ]. In a large meta-analysis incorporating data from 11 studies of 25,369 patients, ALVDD was associated with a 70 percent increased risk for developing symptomatic HF during an average follow-up of 7.9 years [
         <a href="#rid48">
          48
         </a>
         ]. The risk of progression from ALVDD to symptomatic HF with preserved ejection fraction is greatest among patients in whom other cardiac abnormalities subsequently develop, such as reduced LV contractility or contractile reserve, chronotropic incompetence, abnormal vascular function, or cardiac structural remodeling [
         <a href="#rid49">
          49-51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3457.html" rel="external">
          "Pathophysiology of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2650466795">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">
          "Society guideline links: Heart failure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2403005648">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Left ventricular diastolic dysfunction (LVDD) refers broadly to abnormalities in myocardial relaxation, compliance, and filling. LVDD is most commonly identified by echocardiography  (
         <a class="graphic graphic_figure graphicRef72146" href="/z/d/graphic/72146.html" rel="external">
          figure 1
         </a>
         ). LVDD can cause increased LV diastolic filling pressure, which in turn increases pulmonary capillary pressure, resulting in lung congestion and dyspnea. However, LVDD can also be asymptomatic (ALVDD). (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prevalence of ALVDD varies widely depending upon the echocardiographic criteria used. More stringent criteria and adjustment of criteria for age both reduce the measured prevalence of ALVDD. (See
         <a class="local">
          'Prevalence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ALVDD is identified in individuals who have LVDD and no symptoms of HF. (See
         <a class="local">
          'Detection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Echocardiography is the key test for identification of LVDD, assessment of LV ejection fraction, and identification or exclusion of other cardiac abnormalities. LVDD is commonly detected as an incidental finding in patients undergoing transthoracic echocardiography for other indications. An evaluation of diastolic function is a standard component of a complete echocardiographic examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Careful clinical evaluation is required to exclude symptoms of HF. (See
         <a class="local">
          'Exclusion of symptoms of HF'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The management of patients with LVDD involves therapeutic lifestyle changes, treatment of comorbid conditions (including hypertension, diabetes mellitus, coronary heart disease, and obesity), monitoring for symptoms and signs of progression to HF, and prompt evaluation and treatment of incident HF. (See
         <a class="local">
          'Management principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with ALVDD have worse exercise capacity, increased risk of progression to symptomatic HF, and greater mortality compared with those with normal diastolic function. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation 2021; 143:e254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosmala W, Marwick TH. Asymptomatic Left Ventricular Diastolic Dysfunction: Predicting Progression to Symptomatic Heart Failure. JACC Cardiovasc Imaging 2020; 13:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging 2020; 13:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Obokata M, Wiley B, et al. The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. Eur Heart J 2019; 40:3721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obokata M, Olson TP, Reddy YNV, et al. Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. Eur Heart J 2018; 39:2810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbrugge FH, Guazzi M, Testani JM, Borlaug BA. Altered Hemodynamics and End-Organ Damage in Heart Failure: Impact on the Lung and Kidney. Circulation 2020; 142:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosmala W, Jellis CL, Marwick TH. Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure. J Am Coll Cardiol 2015; 65:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh JK, Borlaug BA. Stage B heart failure: is it more common than we think? J Am Coll Cardiol 2015; 65:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacre JW, Wong C, Chan YK, et al. Left Ventricular Dysfunction and Exercise Capacity Trajectory: Implications for Subclinical Heart Failure Staging Criteria. JACC Cardiovasc Imaging 2019; 12:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abhayaratna WP, Marwick TH, Smith WT, Becker NG. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 2006; 92:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuznetsova T, Herbots L, López B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009; 2:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mureddu GF, Agabiti N, Rizzello V, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail 2012; 14:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016; 29:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huttin O, Fraser AG, Coiro S, et al. Impact of Changes in Consensus Diagnostic Recommendations on the Echocardiographic Prevalence of Diastolic Dysfunction. J Am Coll Cardiol 2017; 69:3119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida JG, Fontes-Carvalho R, Sampaio F, et al. Impact of the 2016 ASE/EACVI recommendations on the prevalence of diastolic dysfunction in the general population. Eur Heart J Cardiovasc Imaging 2018; 19:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nayor M, Cooper LL, Enserro DM, et al. Left Ventricular Diastolic Dysfunction in the Community: Impact of Diagnostic Criteria on the Burden, Correlates, and Prognosis. J Am Heart Assoc 2018; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah AM, Claggett B, Kitzman D, et al. Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults: The Atherosclerosis Risk in Communities Study. Circulation 2017; 135:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Borlaug BA. What Do You Want From Your Echocardiogram? J Am Heart Assoc 2018; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obokata M, Kane GC, Reddy YN, et al. Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. Circulation 2017; 135:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. Cardiol Clin 2011; 29:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ. CMR in the Evaluation of Diastolic Dysfunction and Phenotyping of HFpEF: Current Role and Future Perspectives. JACC Cardiovasc Imaging 2020; 13:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mordi IR, Singh S, Rudd A, et al. Comprehensive Echocardiographic and Cardiac Magnetic Resonance Evaluation Differentiates Among Heart Failure With Preserved Ejection Fraction Patients, Hypertensive Patients, and Healthy Control Subjects. JACC Cardiovasc Imaging 2018; 11:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akincioglu C, Berman DS, Nishina H, et al. Assessment of diastolic function using 16-frame 99mTc-sestamibi gated myocardial perfusion SPECT: normal values. J Nucl Med 2005; 46:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett NM, Qamruddin S, Colletti PM. Diastolic function with 16-phase gated myocardial perfusion SPECT. Clin Nucl Med 2014; 39:e355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020; 17:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folsom AR, Shah AM, Lutsey PL, et al. American Heart Association's Life's Simple 7: Avoiding Heart Failure and Preserving Cardiac Structure and Function. Am J Med 2015; 128:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uijl A, Koudstaal S, Vaartjes I, et al. Risk for Heart Failure: The Opportunity for Prevention With the American Heart Association's Life's Simple 7. JACC Heart Fail 2019; 7:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howden EJ, Sarma S, Lawley JS, et al. Reversing the Cardiac Effects of Sedentary Aging in Middle Age-A Randomized Controlled Trial: Implications For Heart Failure Prevention. Circulation 2018; 137:1549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Florido R, Kwak L, Lazo M, et al. Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study. J Am Heart Assoc 2020; 9:e014885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeffer MA. Heart Failure and Hypertension: Importance of Prevention. Med Clin North Am 2017; 101:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373:2103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010; 55:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundström J, Bruze G, Ottosson J, et al. Weight Loss and Heart Failure: A Nationwide Study of Gastric Bypass Surgery Versus Intensive Lifestyle Treatment. Circulation 2017; 135:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rayner JJ, Peterzan MA, Watson WD, et al. Myocardial Energetics in Obesity: Enhanced ATP Delivery Through Creatine Kinase With Blunted Stress Response. Circulation 2020; 141:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Anantha-Narayanan M, Obokata M, et al. Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis. JACC Heart Fail 2019; 7:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorimachi H, Obokata M, Omote K, et al. Long-Term Changes in Cardiac Structure and Function Following Bariatric Surgery. J Am Coll Cardiol 2022; 80:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011; 306:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogel MW, Slusser JP, Hodge DO, Chen HH. The natural history of preclinical diastolic dysfunction: a population-based study. Circ Heart Fail 2012; 5:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa de Sa DD, Hodge DO, Slusser JP, et al. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 2010; 96:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam CS, Lyass A, Kraigher-Krainer E, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011; 124:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aljaroudi W, Alraies MC, Halley C, et al. Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 2012; 125:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borlaug BA, Redfield MM, Melenovsky V, et al. Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail 2013; 6:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wohlfahrt P, Redfield MM, Lopez-Jimenez F, et al. Impact of general and central adiposity on ventricular-arterial aging in women and men. JACC Heart Fail 2014; 2:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Echouffo-Tcheugui JB, Erqou S, Butler J, et al. Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis. JACC Heart Fail 2016; 4:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010; 56:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosmala W, Rojek A, Przewlocka-Kosmala M, et al. Contributions of Nondiastolic Factors to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 2016; 67:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah AM, Claggett B, Loehr LR, et al. Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. Circulation 2017; 135:224.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 131241 Version 3.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33501848" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31005530" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Asymptomatic Left Ventricular Diastolic Dysfunction: Predicting Progression to Symptomatic Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31202759" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31609443" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29788047" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32897746" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Altered Hemodynamics and End-Organ Damage in Heart Failure: Impact on the Lung and Kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25533754" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25533755" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Stage B heart failure: is it more common than we think?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29454775" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Left Ventricular Dysfunction and Exercise Capacity Trajectory: Implications for Subclinical Heart Failure Staging Criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33663906" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12517230" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19187853" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Recommendations for the evaluation of left ventricular diastolic function by echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16488928" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19808325" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prevalence of left ventricular diastolic dysfunction in a general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22562498" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27037982" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28641802" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Impact of Changes in Consensus Diagnostic Recommendations on the Echocardiographic Prevalence of Diastolic Dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29236978" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Impact of the 2016 ASE/EACVI recommendations on the prevalence of diastolic dysfunction in the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29858363" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Left Ventricular Diastolic Dysfunction in the Community: Impact of Diagnostic Criteria on the Burden, Correlates, and Prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27927714" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults: The Atherosclerosis Risk in Communities Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29858373" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : What Do You Want From Your Echocardiogram?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28039229" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21459248" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Invasive hemodynamic assessment in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31202753" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : CMR in the Evaluation of Diastolic Dysfunction and Phenotyping of HFpEF: Current Role and Future Perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28823736" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Comprehensive Echocardiographic and Cardiac Magnetic Resonance Evaluation Differentiates Among Heart Failure With Preserved Ejection Fraction Patients, Hypertensive Patients, and Healthy Control Subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16000278" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Assessment of diastolic function using 16-frame 99mTc-sestamibi gated myocardial perfusion SPECT: normal values.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24893129" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Diastolic function with 16-phase gated myocardial perfusion SPECT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32231333" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Evaluation and management of heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25908393" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : American Heart Association's Life's Simple 7: Avoiding Heart Failure and Preserving Cardiac Structure and Function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31302040" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risk for Heart Failure: The Opportunity for Prevention With the American Heart Association's Life's Simple 7.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29311053" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Reversing the Cardiac Effects of Sedentary Aging in Middle Age-A Randomized Controlled Trial: Implications For Heart Failure Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32390492" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27884228" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Heart Failure and Hypertension: Importance of Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26551272" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20117433" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28258170" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Weight Loss and Heart Failure: A Nationwide Study of Gastric Bypass Surgery Versus Intensive Lifestyle Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32138541" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Myocardial Energetics in Obesity: Enhanced ATP Delivery Through Creatine Kinase With Blunted Stress Response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31302042" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36229085" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Long-Term Changes in Cardiac Structure and Function Following Bariatric Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21862747" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Progression of left ventricular diastolic dysfunction and risk of heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22278404" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The natural history of preclinical diastolic dysfunction: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20350989" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Progression of preclinical diastolic dysfunction to the development of symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21670229" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22261198" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23811963" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Longitudinal changes in left ventricular stiffness: a community-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25194285" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Impact of general and central adiposity on ventricular-arterial aging in women and men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26682794" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20813282" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26868691" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Contributions of Nondiastolic Factors to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27881564" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
